Medexgen Incorporated
Records under this name other than the patents Medexgen Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 6 of 6 · Back to Medexgen Incorporated
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,569,361 | Thrombopoietin protein variants Term ended Term ended May 27, 2024 · From the USPTO record | Term ended | Term ended May 27, 2024 | From the USPTO record |
| US 7,229,962 | Tetravalent etanercept Term ended Term ended Mar 4, 2024 · From the USPTO record | Term ended | Term ended Mar 4, 2024 | From the USPTO record |
| US 10,369,235 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof Lapsed on the fee record Ended Aug 6, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 6, 2023 | From the USPTO record |
| US 7,670,602 | Concatameric immunoadhesion molecule Term ended Term ended May 7, 2023 · From the USPTO record | Term ended | Term ended May 7, 2023 | From the USPTO record |
| US 8,372,961 | Polynucleotides encoding concatameric immunoadhesion molecules Term ended Term ended Jul 26, 2022 · From the USPTO record | Term ended | Term ended Jul 26, 2022 | From the USPTO record |
| US 9,598,683 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof Lapsed on the fee record Ended Mar 21, 2021 · From the USPTO record | Lapsed on the fee record | Ended Mar 21, 2021 | From the USPTO record |